@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix species: . @prefix occursIn: . @prefix obo: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:3176; a Protein: . sub:_2 geneProductOf: hgnc:3059; a Protein: . sub:_3 occursIn: obo:CL_0000076, obo:UBERON_0002367, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:EDN1) -> p(HGNC:HBEGF)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Treatment of cells with GPCR agonists such as endothelin- 1 (ET-1), thrombin, bombesin, and lysophosphatidic acid (LPA) transactivates ErbB1 (reviewed by Zwick et al. [48]). Mechanistically, the process involves rapid stimulation of metalloproteinases followed by cleavage of an ErbB1 ligand precursor, e.g., pro-HB-EGF [49], whose binding activates ErbB1 and downstream signaling pathways"; prov:wasQuotedFrom pubmed:12648469 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12648469; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:32:00.323+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }